Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.66 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 5/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 3/20 | 0.48 |
| ▸ | RXRB | P28702 | 3/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440013 | 0.87 | FFAR4 (0.66) | FFAR4FFAR1PTGER1PTGER4PTGER3 | |
| SCHEMBL3738386 | 0.83 | FFAR1 (0.54) | FFAR4FFAR1PTGDR2 | |
| SCHEMBL3746249 | 0.83 | FFAR1 (0.50) | FFAR4FFAR1PTGDR2 | |
| SCHEMBL14686251 | 0.79 | FFAR1 (0.49) | FFAR4FFAR1PTGDR2 | |
| SCHEMBL31212507 | 0.79 | PTGER4 (0.77) | FFAR4FFAR1PTGER1PTGER4PTGER3 | |
| SCHEMBL1261128 | 0.79 | PTGER4 (0.77) | FFAR4FFAR1PTGER1PTGER4PTGER3 | |
| SCHEMBL1768167 | 0.79 | PTGER1 (0.54) | FFAR4FFAR1PTGER1PTGER4PTGER3 | |
| SCHEMBL760901 | 0.78 | FFAR1 (0.47) | FFAR4FFAR1PTGDR2 | |
| SCHEMBL759109 | 0.78 | FFAR1 (0.46) | FFAR4FFAR1PTGDR2 | |
| SCHEMBL31464099 | 0.78 | FFAR1 (0.46) | FFAR4FFAR1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | claimed |
| US-7829721-B2 | Specific caspase-10 inhibitors | MERCK PATENT GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP5 | FFAR4 860/4885FFAR1 624/4885PTGER1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.